NTRA

XNAS

Natera, Inc.

Mkt Cap $29.4BSERVICES-MEDICAL LABORATORIES

FUNDAMENTALS

P/S

15.61

EV/EBITDA

-140.12

P/B

22.01

P/FCF

373.64

EPS (TTM)

$-1.58

ROE

-12.8%

ROA

-8.7%

FCF

$104.5M

MKT CAP

$39.0B

TECHNICAL ANALYSIS

Mixed

RSI-14

77.7

Strongly Overbought

MACD

0.000

Neutral

SMA-50

$-1.00

SMA-200

$-1.00

BOLL %B

1.08

Above upper band

ATR-14

$12.63

RVOL

1.07x

Normal

MOMENTUM

+19.0%

10d +28.4% / 30d +38.3%

AI PREDICTION · 3-MONTH VIEW

▲Strong edge over the market

NTRA holds a similar standing over 1 and 3 months.

WHERE IT RANKS · vs 2,129 names

20-DAY

▲Top 6%#125

60-DAY

▲Top 3%#58

TYPICAL 3-MO RANGE · vs S&P 500

+0.1%leans upper+1.1%

▸ Horizon detail

20dTop 6%

60dTop 3%

1y+analyst mean$264.61-5.0%

⚡ AI INSIGHT

Our model reads NTRA as strong both near-term and over the next few months. Analysts agree (89% Buy) — the bull case lines up.

RECENT CATALYSTS

ANALYST_ACTIONSBTIG main21d
ANALYST_ACTIONSBarclays main21d
ANALYST_ACTIONSBTIG main21d
ANALYST_ACTIONSRBC Capital reit32d
ANALYST_ACTIONSGoldman Sachs init coverage Neutral32d

REVENUE & GROWTH

$697M

Revenue

+0.0%

QoQ

+0.4%

YoY

Gross Margin

0.6%Expanding

ANALYST CONSENSUS

89% Buy

24 Buy3 Hold0 Sell

Low

$195

Mean

$265

High

$315

SHORT & FLOAT

Free Float

95.5%

2.8 days to cover.

Latest Headlines

The Disinflation Trade Has A New Address: Genomics

SeekingAlpha6/26/2026

Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation

Benzinga6/25/2026

Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer

Benzinga6/24/2026

BTIG Maintains Buy on Natera, Raises Price Target to $275

Benzinga6/24/2026

Barclays Maintains Overweight on Natera, Lowers Price Target to $260

Benzinga6/24/2026

NTRATARGETTarget hit6d ago